8 November 2024 - On 10 October, the High Authority for Health (HAS) issued a negative decision on the request for early access authorisation made by Biogen, concerning the drug Qalsody (tofersen), which aims to slow the progression of a genetic form of Charcot's disease. 

While it is well aware of the seriousness of this pathology and shares the hope that the arrival of a treatment can inspire for all the patients concerned, the HAS recalls that all its decisions and opinions are based on precise and regulated scientific criteria.

Read Haute Autorité de Santé press release